EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Amantadine Use in Severe Traumatic Brain Injury

Shea E Fincher, Madison B Battersby, Matthew C Fitzpatrick, Zachary T Fitzgerald iD, Isabella Lombardozzi, John Peterson iD, Amy Hamrick, Sarah W Frye, Miles Lane, Kristine Lombardozzi

The American Surgeon™ · 28.07.2026

DOI: 10.1177/00031348261472848 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The American Surgeon™, online erschienen am 28.07.2026. Verfasst von Shea E Fincher und 9 weiteren Autor:innen. Beteiligte Einrichtung: Trauma and Critical Care Surgery, Spartanburg Regional Healthcare System, Spartanburg, SC, USA. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amantadine, a weak noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with dopaminergic activity, has emerged as a promising adjunctive therapy in the management of traumatic brain injury (TBI), particularly in patients with disorders of consciousness. Although historically utilized for the treatment of Influenza A and Parkinson’s disease, growing evidence supports its role in promoting neurocognitive recovery following TBI. This review synthesizes preclinical and clinical literature evaluating the pharmacologic mechanisms, therapeutic efficacy, dosing strategies, and safety profile of amantadine in TBI. Clinical trials demonstrate accelerated recovery of consciousness and improved functional outcomes, particularly during the subacute phase of injury. Despite demonstrated benefits and generally favorable safety profile, significant heterogeneity exists in patient selection, dosing and treatment duration, and the standardization of treatment algorithms. This review serves to consolidate the current evidence base, clarify the mechanistic rationale for amantadine use in TBI, and provide a clinically grounded framework to guide its responsible and effective application within the context of neurological rehabilitation.

Schlagwörter

Stichwörter der Autor:innen

Traumatic Brain Injury (TBI)amantadinedisorders of consciousnessdopaminergic modulationneurocognitive recovery

Autor:innen und Institutionen

  • Trauma and Critical Care Surgery, Spartanburg Regional Healthcare System, Spartanburg, SC, USA.
  • Medical Student, Edward Via College of Osteopathic Medicine - Carolinas, Spartanburg, SC, USA.

ORCID-Profile: Zachary T Fitzgerald, John Peterson

Zitieren

APA

Fincher, S. E., Battersby, M. B., Fitzpatrick, M. C., Fitzgerald, Z. T., Lombardozzi, I., Peterson, J., Hamrick, A., Frye, S. W., Lane, M., & Lombardozzi, K. (2026). Amantadine Use in Severe Traumatic Brain Injury. The American Surgeon™. https://doi.org/10.1177/00031348261472848

Vancouver

Fincher SE, Battersby MB, Fitzpatrick MC, Fitzgerald ZT, Lombardozzi I, Peterson J, et al. Amantadine Use in Severe Traumatic Brain Injury. The American Surgeon™. 2026. doi:10.1177/00031348261472848

BibTeX
@article{Fincher2026,
  author = {Fincher, Shea E and Battersby, Madison B and Fitzpatrick, Matthew C and Fitzgerald, Zachary T and Lombardozzi, Isabella and Peterson, John and Hamrick, Amy and Frye, Sarah W and Lane, Miles and Lombardozzi, Kristine},
  title = {Amantadine Use in Severe Traumatic Brain Injury},
  journal = {The American Surgeon™},
  year = {2026},
  doi = {10.1177/00031348261472848}
}
Kostenlos starten →